A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VEC-162 [tasimelteon] (20 mg/day and 50 mg/day) in the treatment of primary insomnia

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VEC-162 [tasimelteon] (20 mg/day and 50 mg/day) in the treatment of primary insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Insomnia
  • Focus Registrational; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2008 Primary endpoint met; results reported in a Vanda Pharmaceuticals media release.
    • 01 May 2008 Top-line results are expected to be reported in June 2008, according to a Vana Pharmaceuticals media release..
    • 04 Mar 2008 The expected completion date for this trial is now 1 Jun 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top